Tim Chiang
Stock Analyst at Capital One
(1.11)
# 3,433
Out of 4,829 analysts
21
Total ratings
31.25%
Success rate
-5.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Chiang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRTX Heron Therapeutics | Initiates: Overweight | $6 | $2.05 | +192.68% | 1 | Apr 23, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Overweight | n/a | $45.27 | - | 3 | Oct 30, 2023 | |
| JSPR Jasper Therapeutics | Initiates: Overweight | $70 | $4.74 | +1,376.79% | 1 | Aug 11, 2023 | |
| AMPH Amphastar Pharmaceuticals | Initiates: Overweight | $44 | $24.34 | +80.77% | 2 | Jul 29, 2022 | |
| KALA KALA BIO | Maintains: Outperform | $300 → $200 | $3.50 | +5,614.29% | 2 | Mar 30, 2022 | |
| PCRX Pacira BioSciences | Maintains: Market Perform | $75 → $66 | $25.09 | +163.05% | 3 | May 5, 2021 | |
| RPTX Repare Therapeutics | Initiates: Outperform | n/a | $1.36 | - | 1 | Oct 28, 2020 | |
| VRCA Verrica Pharmaceuticals | Initiates: Outperform | $21 | $0.51 | +4,047.74% | 1 | Jun 24, 2020 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Neutral | n/a | $17.96 | - | 6 | Sep 17, 2018 | |
| SMMT Summit Therapeutics | Initiates: Buy | $33 | $25.26 | +30.64% | 1 | Feb 13, 2018 |
Heron Therapeutics
Apr 23, 2024
Initiates: Overweight
Price Target: $6
Current: $2.05
Upside: +192.68%
Protagonist Therapeutics
Oct 30, 2023
Initiates: Overweight
Price Target: n/a
Current: $45.27
Upside: -
Jasper Therapeutics
Aug 11, 2023
Initiates: Overweight
Price Target: $70
Current: $4.74
Upside: +1,376.79%
Amphastar Pharmaceuticals
Jul 29, 2022
Initiates: Overweight
Price Target: $44
Current: $24.34
Upside: +80.77%
KALA BIO
Mar 30, 2022
Maintains: Outperform
Price Target: $300 → $200
Current: $3.50
Upside: +5,614.29%
Pacira BioSciences
May 5, 2021
Maintains: Market Perform
Price Target: $75 → $66
Current: $25.09
Upside: +163.05%
Repare Therapeutics
Oct 28, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.36
Upside: -
Verrica Pharmaceuticals
Jun 24, 2020
Initiates: Outperform
Price Target: $21
Current: $0.51
Upside: +4,047.74%
Teva Pharmaceutical Industries
Sep 17, 2018
Upgrades: Neutral
Price Target: n/a
Current: $17.96
Upside: -
Summit Therapeutics
Feb 13, 2018
Initiates: Buy
Price Target: $33
Current: $25.26
Upside: +30.64%